Johnson & Johnson's ICOTYDE Shows Significant Improvement in Psoriasis with New Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 23 hours ago
0mins
Should l Buy JNJ?
Source: NASDAQ.COM
- Clinical Trial Results: Johnson & Johnson's ICOTYDE achieved up to 49% complete skin clearance in the ICONIC-ADVANCE 1 and 2 studies at 52 weeks, significantly improving from 41% at 24 weeks, indicating its effectiveness in treating moderate-to-severe psoriasis.
- Patient Transition Impact: Patients switching from placebo to ICOTYDE at Week 16 achieved clearance rates of 50% and 43% by Week 52, demonstrating the drug's rapid efficacy and enhancing its clinical application potential.
- Sustained Efficacy in Adolescents: In the ICONIC-LEAD study, nearly 60% of adolescent patients achieved complete skin clearance at Week 52, with 86% reaching PASI 90 response, indicating ICOTYDE's durable efficacy and safety across different age groups.
- Safety Profile Analysis: The safety profile of ICOTYDE remained consistent with earlier data, with no new safety signals identified, and overall adverse event and infection rates lower than those observed with the comparator drug deucravacitinib, further solidifying its position as a safe and effective oral therapy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 239.240
Low
190.00
Averages
218.50
High
240.00
Current: 239.240
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Deutsche Bank Sees AtaiBeckley as a Leader in Psychedelic Renaissance
- Positive Market Outlook: Deutsche Bank initiated coverage on AtaiBeckley with a buy rating and a $12 price target, indicating over a 250% upside from Friday's close, reflecting strong market confidence in its position within the psychedelic drug sector.
- Drug Development Potential: AtaiBeckley is developing two key drugs for treatment-resistant depression, BPL-003 and VLS-01, with potential U.S. sales peaking at $4 billion and $2 billion respectively, highlighting significant market opportunities for its product pipeline.
- Increased Industry Recognition: As psychedelic therapies gain popularity in mental health treatment, Deutsche Bank's analyst noted that AtaiBeckley has emerged as a bona fide drug developer, attracting interest from investors typically focused on conventional therapeutics, underscoring its leadership in this nascent market.
- FDA Regulatory Changes: Hoang mentioned that the FDA's skepticism towards psychedelic therapies has eased, with expectations that upon FDA approval, these drugs will undergo federal rescheduling within 90 days, further enhancing market acceptance and investor confidence.
See More
Johnson & Johnson's ICOTYDE Shows Significant Improvement in Psoriasis with New Data
- Clinical Trial Results: Johnson & Johnson's ICOTYDE achieved up to 49% complete skin clearance in the ICONIC-ADVANCE 1 and 2 studies at 52 weeks, significantly improving from 41% at 24 weeks, indicating its effectiveness in treating moderate-to-severe psoriasis.
- Patient Transition Impact: Patients switching from placebo to ICOTYDE at Week 16 achieved clearance rates of 50% and 43% by Week 52, demonstrating the drug's rapid efficacy and enhancing its clinical application potential.
- Sustained Efficacy in Adolescents: In the ICONIC-LEAD study, nearly 60% of adolescent patients achieved complete skin clearance at Week 52, with 86% reaching PASI 90 response, indicating ICOTYDE's durable efficacy and safety across different age groups.
- Safety Profile Analysis: The safety profile of ICOTYDE remained consistent with earlier data, with no new safety signals identified, and overall adverse event and infection rates lower than those observed with the comparator drug deucravacitinib, further solidifying its position as a safe and effective oral therapy.
See More
Iran War Effects Widen, Pressuring Stock Markets
- Oil Price Surge Impact: The ongoing war in Iran has led to a 5.5% increase in West Texas Intermediate crude to $99.64 per barrel and a 4.2% rise in Brent crude to $112.57, causing the Dow and Nasdaq to drop 1.7% and 2.2%, respectively, highlighting the market's sensitivity to rising oil prices.
- Tech Stocks Hit Hard: News regarding Anthropic's AI model has severely impacted enterprise software stocks, with CrowdStrike and Palo Alto Networks seeing declines of 6% and over 9%, respectively, reflecting investor concerns about AI potentially replacing traditional software companies and exacerbating market anxiety.
- Meta Platforms Legal Challenges: Meta's stock fell nearly 11.5% after losing two social media addiction lawsuits, raising concerns about the company's short-term performance and long-term legal risks, although analysts believe the company has a strong legal position.
- Costco's Resilience: Despite overall market pressures, Costco's shares rose 1.2% last week, driven by increased customer traffic from higher gas prices and a new standalone gas station initiative, demonstrating the company's ability to find growth opportunities even in challenging conditions.
See More
Impact of Iran War on Global Economies
- Market Focus: Investors are closely monitoring the potential impact of the Iran war on the U.S. and global economies as they head into the Easter week, reflecting market sensitivity to geopolitical risks.
- Economic Outlook Volatility: Analysts warn that escalating conflict could lead to rising energy prices, which may affect inflation and consumer spending, thereby negatively impacting economic growth.
- Investment Strategy Adjustments: Investors may reassess their portfolios, considering allocations to safe-haven assets to mitigate potential market volatility and uncertainty, indicating a cautious market sentiment.
- Global Market Interconnection: The ongoing Iran war could trigger a ripple effect across global markets, particularly in countries heavily reliant on energy, prompting investors to stay alert to developments in related sectors.
See More
Johnson & Johnson Reports New Data on ICOTYDE Skin Clearance Rates
- Clinical Trial Results: Johnson & Johnson presented at the 2026 American Academy of Dermatology Annual Meeting that ICOTYDE's complete skin clearance rates increased from 41% to 49% and from 33% to 48% at Week 52 in the ICONIC-ADVANCE 1 and 2 studies, indicating significant efficacy in treating moderate-to-severe plaque psoriasis.
- Adolescent Patient Performance: In the ICONIC-LEAD study, nearly 60% of adolescents achieved complete skin clearance at Week 52, specifically 57% PASI 100 and 61% IGA 0, demonstrating ICOTYDE's favorable safety and efficacy profile in the adolescent population.
- Safety Analysis: The adverse event profile of ICOTYDE through Week 52 was consistent with that observed at Weeks 16 and 24, with no new safety signals identified, indicating that the drug's long-term safety has been validated, potentially offering patients a more reliable treatment option.
- Market Outlook: The successful clinical data for ICOTYDE not only provides new treatment options for patients but may also enhance Johnson & Johnson's competitiveness in the psoriasis market, addressing the growing patient demand and further solidifying its leadership position in the biopharmaceutical sector.
See More
Johnson & Johnson Reports ICOTYDE Skin Clearance Data
- Clinical Trial Results: Johnson & Johnson presented data at the 2026 American Academy of Dermatology Annual Meeting showing that ICOTYDE's complete skin clearance rates increased from 41% to 49% and from 33% to 48% in the ICONIC-ADVANCE 1 and 2 studies from Week 24 to Week 52, demonstrating significant efficacy in treating moderate-to-severe plaque psoriasis.
- Adolescent Patient Outcomes: In the ICONIC-LEAD study, nearly 60% of adolescents achieved complete skin clearance (57% PASI 100, 61% IGA 0) at Week 52, indicating ICOTYDE's effectiveness and safety in this age group, potentially providing a new treatment option for young patients.
- Safety Profile Analysis: Throughout the 52-week treatment period, no new safety signals were identified for ICOTYDE, and its adverse event and infection rates were lower than those of the comparator drug deucravacitinib, reinforcing patient confidence in its safety.
- Market Potential: As the first targeted oral peptide, ICOTYDE offers a unique treatment option that could transform the treatment landscape for moderate-to-severe plaque psoriasis, addressing the need for long-term effective therapies and presenting significant market opportunities.
See More
Deutsche Bank Sees AtaiBeckley as a Leader in Psychedelic Renaissance
- Positive Market Outlook: Deutsche Bank initiated coverage on AtaiBeckley with a buy rating and a $12 price target, indicating over a 250% upside from Friday's close, reflecting strong market confidence in its position within the psychedelic drug sector.
- Drug Development Potential: AtaiBeckley is developing two key drugs for treatment-resistant depression, BPL-003 and VLS-01, with potential U.S. sales peaking at $4 billion and $2 billion respectively, highlighting significant market opportunities for its product pipeline.
- Increased Industry Recognition: As psychedelic therapies gain popularity in mental health treatment, Deutsche Bank's analyst noted that AtaiBeckley has emerged as a bona fide drug developer, attracting interest from investors typically focused on conventional therapeutics, underscoring its leadership in this nascent market.
- FDA Regulatory Changes: Hoang mentioned that the FDA's skepticism towards psychedelic therapies has eased, with expectations that upon FDA approval, these drugs will undergo federal rescheduling within 90 days, further enhancing market acceptance and investor confidence.
See More
Johnson & Johnson's ICOTYDE Shows Significant Improvement in Psoriasis with New Data
- Clinical Trial Results: Johnson & Johnson's ICOTYDE achieved up to 49% complete skin clearance in the ICONIC-ADVANCE 1 and 2 studies at 52 weeks, significantly improving from 41% at 24 weeks, indicating its effectiveness in treating moderate-to-severe psoriasis.
- Patient Transition Impact: Patients switching from placebo to ICOTYDE at Week 16 achieved clearance rates of 50% and 43% by Week 52, demonstrating the drug's rapid efficacy and enhancing its clinical application potential.
- Sustained Efficacy in Adolescents: In the ICONIC-LEAD study, nearly 60% of adolescent patients achieved complete skin clearance at Week 52, with 86% reaching PASI 90 response, indicating ICOTYDE's durable efficacy and safety across different age groups.
- Safety Profile Analysis: The safety profile of ICOTYDE remained consistent with earlier data, with no new safety signals identified, and overall adverse event and infection rates lower than those observed with the comparator drug deucravacitinib, further solidifying its position as a safe and effective oral therapy.
See More
Iran War Effects Widen, Pressuring Stock Markets
- Oil Price Surge Impact: The ongoing war in Iran has led to a 5.5% increase in West Texas Intermediate crude to $99.64 per barrel and a 4.2% rise in Brent crude to $112.57, causing the Dow and Nasdaq to drop 1.7% and 2.2%, respectively, highlighting the market's sensitivity to rising oil prices.
- Tech Stocks Hit Hard: News regarding Anthropic's AI model has severely impacted enterprise software stocks, with CrowdStrike and Palo Alto Networks seeing declines of 6% and over 9%, respectively, reflecting investor concerns about AI potentially replacing traditional software companies and exacerbating market anxiety.
- Meta Platforms Legal Challenges: Meta's stock fell nearly 11.5% after losing two social media addiction lawsuits, raising concerns about the company's short-term performance and long-term legal risks, although analysts believe the company has a strong legal position.
- Costco's Resilience: Despite overall market pressures, Costco's shares rose 1.2% last week, driven by increased customer traffic from higher gas prices and a new standalone gas station initiative, demonstrating the company's ability to find growth opportunities even in challenging conditions.
See More
Impact of Iran War on Global Economies
- Market Focus: Investors are closely monitoring the potential impact of the Iran war on the U.S. and global economies as they head into the Easter week, reflecting market sensitivity to geopolitical risks.
- Economic Outlook Volatility: Analysts warn that escalating conflict could lead to rising energy prices, which may affect inflation and consumer spending, thereby negatively impacting economic growth.
- Investment Strategy Adjustments: Investors may reassess their portfolios, considering allocations to safe-haven assets to mitigate potential market volatility and uncertainty, indicating a cautious market sentiment.
- Global Market Interconnection: The ongoing Iran war could trigger a ripple effect across global markets, particularly in countries heavily reliant on energy, prompting investors to stay alert to developments in related sectors.
See More
Johnson & Johnson Reports New Data on ICOTYDE Skin Clearance Rates
- Clinical Trial Results: Johnson & Johnson presented at the 2026 American Academy of Dermatology Annual Meeting that ICOTYDE's complete skin clearance rates increased from 41% to 49% and from 33% to 48% at Week 52 in the ICONIC-ADVANCE 1 and 2 studies, indicating significant efficacy in treating moderate-to-severe plaque psoriasis.
- Adolescent Patient Performance: In the ICONIC-LEAD study, nearly 60% of adolescents achieved complete skin clearance at Week 52, specifically 57% PASI 100 and 61% IGA 0, demonstrating ICOTYDE's favorable safety and efficacy profile in the adolescent population.
- Safety Analysis: The adverse event profile of ICOTYDE through Week 52 was consistent with that observed at Weeks 16 and 24, with no new safety signals identified, indicating that the drug's long-term safety has been validated, potentially offering patients a more reliable treatment option.
- Market Outlook: The successful clinical data for ICOTYDE not only provides new treatment options for patients but may also enhance Johnson & Johnson's competitiveness in the psoriasis market, addressing the growing patient demand and further solidifying its leadership position in the biopharmaceutical sector.
See More
Johnson & Johnson Reports ICOTYDE Skin Clearance Data
- Clinical Trial Results: Johnson & Johnson presented data at the 2026 American Academy of Dermatology Annual Meeting showing that ICOTYDE's complete skin clearance rates increased from 41% to 49% and from 33% to 48% in the ICONIC-ADVANCE 1 and 2 studies from Week 24 to Week 52, demonstrating significant efficacy in treating moderate-to-severe plaque psoriasis.
- Adolescent Patient Outcomes: In the ICONIC-LEAD study, nearly 60% of adolescents achieved complete skin clearance (57% PASI 100, 61% IGA 0) at Week 52, indicating ICOTYDE's effectiveness and safety in this age group, potentially providing a new treatment option for young patients.
- Safety Profile Analysis: Throughout the 52-week treatment period, no new safety signals were identified for ICOTYDE, and its adverse event and infection rates were lower than those of the comparator drug deucravacitinib, reinforcing patient confidence in its safety.
- Market Potential: As the first targeted oral peptide, ICOTYDE offers a unique treatment option that could transform the treatment landscape for moderate-to-severe plaque psoriasis, addressing the need for long-term effective therapies and presenting significant market opportunities.
See More
